AwardJun 15, 2026, 04:07 PM
Nyxoah's Genio® Wins Prix Galien UK 2026 for Best Medical Technology
AI Summary
Nyxoah SA announced that its Genio® hypoglossal nerve stimulation therapy for Obstructive Sleep Apnea (OSA) received the prestigious Prix Galien UK 2026 Award for Best Medical Technology. This award is a significant recognition of Genio's impact on patient care and outcomes. The company highlighted recent business momentum, including FDA approval and commercial launch in the U.S., new financing to accelerate U.S. expansion, and increasing adoption across Europe and other international markets.
Key Highlights
- Nyxoah's Genio® system won the Prix Galien UK 2026 Award for Best Medical Technology.
- The award recognizes Genio's contribution to treating Obstructive Sleep Apnea (OSA).
- The company recently achieved FDA approval and commercial launch of Genio in the U.S.
- Nyxoah secured new financing to accelerate its U.S. expansion.
- Genio adoption continues to grow across Europe and other international markets.
- Genio received its European CE Mark in 2019.
- FDA approved Genio in August 2025 for a subset of adult OSA patients.
Price Impact
More from NYXH